

# Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass and SHANGHAI, China, September 1, 2022 (GLOBE NEWSWIRE) – Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer. Dr. Lowry brings over 20 years of broad clinical expertise in the design and execution of early to late-stage clinical programs to Zenas, where he will lead the company’s global clinical, medical affairs, and pharmacovigilance functions.

“We are delighted to welcome Dr. Lowry to Zenas at this pivotal time for the company as we commence two phase three registration trials for our lead product candidate, obexelimab, in the fourth quarter of this year and initiate first-in-human clinical trials for multiple pipeline programs” said Hua Mu, M.D., Ph. D, Chief Executive Officer at Zenas. “Dr. Lowry’s proven leadership, broad clinical development background, and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to patients.”

Dr. Simon Lowry added, “There are many patients with autoimmune and rare diseases in need of effective new treatment options. The deeply experienced and talented Zenas team has made impressive progress advancing the company’s pipeline in a very short period of time, and I look forward to leading the ongoing advancement of Zenas’ clinical programs through commercialization while further expanding the company’s pipeline of innovative programs.”

Dr. Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programs, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine, including rheumatology, immunology, and ophthalmology. Prior to joining Zenas, Dr. Lowry was Chief Medical Officer at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, leading all development stage immunology assets into clinical development, and served as a key member of the leadership team. He also served as Chief Medical Officer at Sun Pharma

North America, where he was responsible for four branded therapeutic areas (Immunology & Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions (including clinical development, medical information, field medical, HEOR, publications / medical communications, and operations). Early in his career, he worked at Novartis, where he served as Vice President, Global Medical Affairs Franchise Head, Immunology & Dermatology, and Pfizer, where he served in roles of increasing responsibility, including as Vice President, Oncology Medical Affairs Group Leader.

Prior to his pharmaceutical/ biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK and Australia. He received his BA from Trinity Hall, Cambridge University, UK and his MB BChir medical degree from Cambridge University School of Clinical Medicine.

### **About Zenas BioPharma**

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations in the US and China, Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit [www.zenasbio.com](http://www.zenasbio.com) and follow us on Twitter at [@ZenasBioPharma](https://twitter.com/ZenasBioPharma) and [LinkedIn](https://www.linkedin.com/company/zenasbio).

### **Investor and Media Contact:**

Joe Farmer  
Zenas BioPharma  
[IR@zenasbio.com](mailto:IR@zenasbio.com)

# Zenas BioPharma 任命 Simon Lowry 博士担任首席医学官

美国马萨诸塞州沃尔瑟姆和中国上海，2022年9月6日（GLOBE NEWSWIRE）  
- 致力于成为世界各地患者免疫疗法开发与商业化领先企业的全球性生物制药公司 Zenas BioPharma（泽纳仕生物医药），今日宣布任命 Simon Lowry 医学博士担任其首席医学官。Lowry 博士为 Zenas 带来了 20 多年在早期至晚期临床项目设计和执行方面的广泛临床专业知识，他将领导该公司的全球临床、医学事务及药物警戒职能。

Zenas 首席执行官牟骅博士表示：“我们将于今年第四季度开始先导候选产品 Obixelimab 的两项三期注册临床试验，同时启动多个管线项目的首次人体临床试验。我们很高兴地欢迎 Lowry 博士在这个关键时刻加入 Zenas。Lowry 博士久经考验的领导能力、广泛的临床开发背景和丰富的全球临床试验经验将进一步增强我们的能力以践行我们的使命，即通过为患者提供一流的免疫疗法，从而改变医疗需求尚未得到满足患者的生活。”

Simon Lowry 博士补充道：“许多自身免疫疾病和罕见病患者都需要有效的新治疗方案。经验丰富、才华横溢的 Zenas 团队在极短的时间内推进了公司的产品管线，取得了令人瞩目的进展，我期待领导继续推进 Zenas 的临床项目进入商业化，同时进一步扩大公司的创新项目管线。”

Lowry 博士是一位医学博士，在大型和新兴制药及生物技术公司拥有 20 年的经验，领导主持了众多成功的开发项目、领导临床和医学事务团队，并在包括风湿病学、免疫学和眼科学等多个医学领域与监管机构互动交流。在加入 Zenas 之前，Lowry 博士曾担任 Kinevant Sciences 的首席医学官，这是一家临床阶段生物制药公司，致力于治疗罕见的炎症性和自身免疫疾病。Lowry 博士曾担任 Roivant Sciences 公司的免疫学研发主管，领导所有开发阶段的免疫学资产进入临床开发，并担任领导团队的关键成员。他还曾担任 Sun Pharma North America 的首席

医学官，负责免疫学与皮肤病学、眼科学、神经病学和肿瘤学这四大类治疗领域，并领导所有的开发和医学职能（包括临床开发、医学信息、驻地医学事务、HEOR、出版物/医学通讯，和运营）。Lowry 在职业生涯早期，曾在 Novartis 工作过，担任副总裁、免疫学与皮肤病学全球医学事务部门负责人；也曾在 Pfizer 工作过，担任持续上升的职位，包括副总裁、肿瘤学医学事务团队负责人。

Lowry 博士在从事制药/生物技术职业之前，曾在英国和澳大利亚的多家机构从事内科工作。他在英国剑桥大学三一学院获得学士学位，在剑桥大学临床医学院获得内外全科医学学士（MB, BChir）学位。

### 关于 Zenas BioPharma

Zenas BioPharma 是一家全球性生物制药公司，致力于成为世界各地患者免疫疗法开发与商业化的领先企业。通过在美国和中国开展临床开发及运营，Zenas 正在快速推进其深厚的创新治疗药物研发管线，并通过我们成功的商务拓展战略不断发展。我们经验丰富的领导团队和广泛的业务合作伙伴共同致力于推动卓越运营，为自身免疫疾病和罕见病患者提供潜在的变革性疗法，从而改善患者的生活。如需了解有关 Zenas BioPharma 的更多信息，请访问 [www.zenasbio.com](http://www.zenasbio.com)，并在 Twitter (@ZenasBioPharma) 和 LinkedIn 上关注我们。

投资者和媒体联系人： Joe Farmer Zenas BioPharma [IR@zenasbio.com](mailto:IR@zenasbio.com)